ethosuximide has been researched along with lacosamide in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Chodkowski, A; Dawidowski, M; Herold, F; Kleps, J; Szulczyk, P; Wilczek, M | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chońska, J; Dawidowski, M; Mika, W; Turło, J | 1 |
| Filipek, B; Kamiński, K; Kieć-Kononowicz, K; Latacz, G; Obniska, J; Rapacz, A; Łuszczki, JJ | 1 |
| Andres-Mach, M; Kamiński, K; Kieć-Kononowicz, K; Latacz, G; Rapacz, A; Zagaja, M; Łuszczki, JJ | 1 |
| Abram, M; Andres-Mach, M; Kamiński, K; Obniska, J; Rapacz, A; Zagaja, M; Łuszczki, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Filipek, B; Furgała, A; Obniska, J; Rapacz, A; Rybka, S; Żmudzki, P | 1 |
| Filipek, B; Kamiński, K; Obniska, J; Rapacz, A | 1 |
| Filipek, B; Obniska, J; Rapacz, A; Rybka, S; Żmudzki, P | 1 |
| Budziszewska, B; Koczurkiewicz, P; Marona, H; Pańczyk, K; Pękala, E; Piska, K; Pytka, K; Rapacz, A; Starek-Świechowicz, B; Waszkielewicz, AM | 1 |
| Jin, DI; Kang, JW; Lee, JE; Lee, SH; Lin, T | 1 |
| Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS | 1 |
| Abram, M; Andres-Mach, M; Esguerra, CV; Gawel, K; Jakubiec, M; Kamiński, K; Latacz, G; Lubelska, A; Nieoczym, D; Pieróg, M; Rapacz, A; Socała, K; Szewczyk, A; Szulczyk, B; Wlaź, P; Zagaja, M; Łuszczki, JJ | 1 |
| Abram, M; Andres-Mach, M; Kaminski, K; Luszczki, J; Maj, M; Rola, R; Szewczyk, A; Zagaja, M | 1 |
| Akat, Ş; Akman, Ö; Çarçak, N; Karanfil, C; Onat, F | 1 |
| Battino, D; Bromley, R; Kochen, S; Meador, KJ; Pennell, PB; Thomas, SV; Tomson, T | 1 |
| Schubert-Bast, S; Strzelczyk, A | 1 |
4 review(s) available for ethosuximide and lacosamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Topics: Acetamides; Acute Kidney Injury; Amines; Anticonvulsants; Carbamates; Critical Illness; Cyclohexanecarboxylic Acids; Dibenzazepines; Dose-Response Relationship, Drug; Ethosuximide; Felbamate; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Isoxazoles; Lacosamide; Lamotrigine; Levetiracetam; Phenobarbital; Phenylcarbamates; Phenylenediamines; Phenytoin; Piracetam; Propylene Glycols; Renal Dialysis; Renal Replacement Therapy; Seizures; Topiramate; Triazines; Valproic Acid; Zonisamide | 2016 |
Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force
Topics: Breast Feeding; Cannabidiol; Carbamazepine; Child; Clobazam; Clonazepam; Epilepsy; Ethosuximide; Everolimus; Felbamate; Female; Fenfluramine; Gabapentin; Humans; Infant; Lacosamide; Lamotrigine; Levetiracetam; Oxcarbazepine; Phenobarbital; Phenytoin; Prospective Studies; Tiagabine; Topiramate; Valproic Acid; Vigabatrin; Zonisamide | 2022 |
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
Topics: Autism Spectrum Disorder; Bromides; Cannabidiol; Clobazam; Cognition; Ethosuximide; Everolimus; Felbamate; Fenfluramine; Humans; Lacosamide; Lamotrigine; Levetiracetam; Pregabalin; Spasms, Infantile; Sulfides; Topiramate; Valproic Acid; Vigabatrin; Zinc Compounds; Zonisamide | 2022 |
14 other study(ies) available for ethosuximide and lacosamide
| Article | Year |
|---|---|
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
Topics: Animals; Anticonvulsants; Diketopiperazines; Electroshock; Epilepsy; Humans; Male; Mice; Models, Molecular; Pentylenetetrazole; Rats; Rats, Sprague-Dawley; Rats, Wistar; Seizures; Sodium Channel Blockers; Sodium Channels | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Epilepsy; Halogenation; Hydrocarbons, Fluorinated; Male; Mice; Molecular Structure; Pentylenetetrazole; Pilocarpine; Pyrazines; Pyrroles; Rats; Rats, Sprague-Dawley; Seizures; Structure-Activity Relationship | 2014 |
Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives.
Topics: Amides; Animals; Anticonvulsants; Benzylamines; Convulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Electroshock; Humans; Imidazoles; Male; Mice; Microsomes, Liver; Molecular Structure; Motor Activity; Pentylenetetrazole; Propionates; Pyrrolidines; Rotarod Performance Test; Seizures; Small Molecule Libraries; Structure-Activity Relationship | 2015 |
Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Electroshock; HEK293 Cells; Humans; Mice; Models, Molecular; Molecular Structure; Motor Activity; Piperazines; Seizures; Structure-Activity Relationship; Succinimides | 2015 |
New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones.
Topics: Analgesics; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Injections, Intraperitoneal; Mice; Molecular Structure; Pain; Pain Measurement; Pentylenetetrazole; Piperazines; Pyrrolidinones; Seizures | 2016 |
Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from 3-(1-phenylethyl)- and 3-benzyl-pyrrolidine-2,5-dione.
Topics: Animals; Anticonvulsants; Calcium Channel Blockers; Calcium Channels, L-Type; GABA-A Receptor Antagonists; Mannich Bases; Mice; Piperazines; Pyrrolidines; Receptors, N-Methyl-D-Aspartate; Sodium Channel Blockers; Structure-Activity Relationship; Succinimides | 2016 |
Design, synthesis and anticonvulsant activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides.
Topics: Amides; Animals; Anticonvulsants; Calcium Channels; Drug Design; Humans; Injections, Intraperitoneal; Mice; Molecular Structure; Neurons; Pyrrolidines; Seizures | 2016 |
Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl-, 3-isopropyl, and 3-benzhydryl analogs.
Topics: Animals; Anticonvulsants; Mannich Bases; Mice; Pyrrolidines; Seizures | 2017 |
Design, synthesis and anticonvulsant-analgesic activity of new
Topics: | 2017 |
Teratogenic potential of antiepileptic drugs in the zebrafish model.
Topics: Acetamides; Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Ethosuximide; Female; Fructose; Humans; Lacosamide; Lamotrigine; Levetiracetam; Piracetam; Pregnancy; Teratogenesis; Topiramate; Triazines; United States; Valproic Acid; Zebrafish | 2013 |
N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a Broad-Spectrum Antiepileptic Drug.
Topics: Animals; Anticonvulsants; Behavior, Animal; Dose-Response Relationship, Drug; Epilepsy; Ethosuximide; Lacosamide; Levetiracetam; Male; Mice; Pentylenetetrazole; Pyrrolidines; Seizures; Valproic Acid; Zebrafish | 2020 |
Evaluation of the impact of compound C11 a new anticonvulsant candidate on cognitive functions and hippocampal neurogenesis in mouse brain.
Topics: Animals; Anticonvulsants; Brain; Cognition; Epilepsy; Ethosuximide; Hippocampus; Lacosamide; Levetiracetam; Male; Mice; Mice, Inbred C57BL; Neurogenesis; Pentylenetetrazole; Spatial Memory | 2020 |
The effect of chronic treatment with sodium channel blocker lacosamide on early development of absence seizures in genetic absence epilepsy rats.
Topics: Animals; Electroencephalography; Epilepsy, Absence; Ethosuximide; Lacosamide; Rats; Rats, Wistar; Seizures; Sodium Channel Blockers | 2022 |